What are the recommended management guidelines for a pregnant woman with a cervical length ≤25 mm before 24 weeks gestation?

Management of Short Cervix in Pregnancy

For a pregnant woman with cervical length ≤25 mm before 24 weeks gestation, prescribe vaginal progesterone (200 mg micronized capsules or 90 mg gel nightly) if the cervix measures ≤20 mm, and strongly consider it for cervical lengths 21-25 mm through shared decision-making; do not place cerclage, do not use 17-hydroxyprogesterone caproate, and do not place a pessary. 1

Diagnostic Approach

Measurement Technique

• All cervical length measurements must be performed transvaginally using standardized procedures per Perinatal Quality Foundation or Fetal Medicine Foundation protocols 1
• Perform assessment at the 18-22 week anatomy ultrasound
• Define short cervix as ≤25 mm in singleton gestations without prior spontaneous preterm birth 1

Common pitfall: Transabdominal measurements are inadequate for therapeutic decision-making. Always confirm with transvaginal ultrasound when cervical shortening is suspected.

Treatment Algorithm for Singleton Gestations

Cervical Length ≤20 mm Before 24 Weeks

Prescribe vaginal progesterone (GRADE 1A recommendation) 1

• Formulations: 200 mg micronized progesterone capsules OR 90 mg (8%) progesterone gel
• Continue nightly until delivery or 36-37 weeks
• This is the strongest evidence-based intervention for reducing preterm birth risk

Cervical Length 21-25 mm Before 24 Weeks

Consider vaginal progesterone based on shared decision-making (GRADE 1B) 1

• Discuss individual risk factors with the patient
• Consider patient preferences and access to medication
• Same dosing as above if initiated

What NOT to Do

Do NOT use 17-alpha hydroxyprogesterone caproate (17-OHPC) 1

• This includes compounded formulations
• FDA withdrew approval in 2023 due to lack of efficacy
• Multiple trials showed no benefit for short cervix without prior preterm birth

Do NOT place cerclage in women without prior spontaneous preterm birth who have cervical length 10-25 mm without cervical dilation (GRADE 1B) 1

• Cerclage has not demonstrated benefit in this population
• Reserve for specific indications only (see below)

Do NOT place cervical pessary (GRADE 1B) 1

• Despite initial promising data, large multinational trials showed no benefit
• The Fetal Medicine Foundation trial of 932 women showed no reduction in preterm birth <34 weeks (12.0% vs 10.8%) 1

Special Populations

Twin Gestations

Do NOT routinely use progesterone, pessary, or cerclage for cervical shortening in twins outside clinical trials (GRADE 1B) 1

• Evidence does not support benefit in multiple gestations
• Management remains expectant with close monitoring

Women with Prior Spontaneous Preterm Birth

This guideline specifically addresses women without prior spontaneous preterm birth. For women with prior preterm birth:

• Different management algorithms apply
• Cerclage may be indicated with cervical length ≤25 mm 2
• Consider history-indicated cerclage for ≥3 prior early preterm births 3

Late Diagnosis (After 24 Weeks)

Recent evidence suggests vaginal progesterone may not be beneficial when short cervix is first identified after 24 weeks 4

• Study of 154 women showed no reduction in preterm birth <37 weeks (24.6% vs 19.1%, P=0.41)
• Time-to-delivery was similar between treated and untreated groups
• Consider expectant management in this scenario

Clinical Context and Nuances

Why This Matters

Preterm birth remains the leading cause of perinatal morbidity and mortality. 90% of deliveries before 34 weeks occur in women with no previous preterm birth history 1. Transvaginal cervical length is one of the best available predictors of spontaneous preterm birth, making appropriate intervention critical.

Strength of Evidence

The 2024 SMFM guidelines 1 represent the most current, authoritative recommendations from the leading maternal-fetal medicine society. The GRADE 1A recommendation for vaginal progesterone at ≤20 mm reflects high-quality evidence with clear benefit and minimal harm.

Addressing Health Disparities

Non-Hispanic Black pregnant individuals have preterm birth rates of 14.4% compared to 9.3% in White individuals 1. These disparities persist even after controlling for socioeconomic factors, emphasizing the importance of:

• Universal access to cervical length screening
• Removing barriers to vaginal progesterone access
• Provider education on proper measurement techniques

Important Counseling Points

• Vaginal progesterone use for short cervix is currently off-label, requiring informed consent
• Most common side effect is increased vaginal discharge
• No significant safety concerns identified in multiple trials
• Cost-effectiveness supports universal screening programs

Critical pitfall: Do not delay treatment while awaiting "further shortening." Initiate vaginal progesterone promptly when criteria are met, as the intervention window is time-sensitive (before 24 weeks).